Investing News NetworkOctober 30, 2024Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) has signed an exclusive licence agreement with UWA, granting worldwide rights to a rapidly growing portfolio of selective serotonin-releasing agents. (See Appendix for Key Commercial Terms). These novel compounds, realised through a UWA–Emyria research partnership launched in 2021,2 include potential next-generation treatments for mental health and neurological conditions such as PTSD and Parkinson’s disease.

投资新闻网2024Emyria Limited（ASX:EMD）（“Emyria”或“公司”）已与UWA签署独家许可协议，授予全球范围内快速增长的选择性血清素释放剂组合的权利。（关键商业条款见附录）。这些新化合物是通过2021年启动的UWA-Emyria研究伙伴关系实现的，2包括潜在的下一代治疗心理健康和神经系统疾病的方法，如创伤后应激障碍和帕金森病。

HIGHLIGHTS Emyria has finalised an important licence agreement with the University of Western Australia (UWA) securing exclusive global rightsto a library of patented, MDMA-inspired selective serotonin-releasing agents. Lead compounds MX-100 and MX-200 are being prepared for advanced screening, targetingmental health conditions like Post-Traumatic StressDisorder (PTSD) and Parkinson’s disease.

亮点Emyria与西澳大利亚大学（UWA）达成了一项重要的许可协议，确保了获得专利的，MDMA启发的选择性血清素释放剂库的独家全球权利。先导化合物MX-100和MX-200正在准备用于高级筛查，针对创伤后应激障碍（PTSD）和帕金森氏病等健康状况。

Supported by a $499,411 WA government grant,1 Emyria is accelerating its drug discovery pipeline with key results set for early2025. As leaders in MDMA-assisted therapy for PTSD, Emyria's pursuit of serotonin-selective compounds aligns with the Company’s commitment to improving treatment outcomes and safety for patients while building a valuable intellectual property portfolio to strengthen our therapeutic offerings.Emyria and UWA’s drug discovery program has demonstrated significant technical breakthroughs in designing compounds with selective serotonin-releasing properties.

在华盛顿州政府499411美元赠款的支持下，1埃米里亚正在加速其药物发现流程，并将于2025年初取得关键成果。。Emyria和UWA的药物发现计划在设计具有选择性5-羟色胺释放特性的化合物方面取得了重大的技术突破。

Through advanced medicinal chemistry, the team has successfully created compounds that induce serotonin release without releasing dopamine or noradrenaline. This selectivity is critical for reducing side effects of MDMA such as euphoria and elevated blood pressure/heart rate, making the compounds better suited for .

通过先进的药物化学，该团队成功地创造了诱导血清素释放而不释放多巴胺或去甲肾上腺素的化合物。这种选择性对于减少MDMA的副作用至关重要，例如欣快和血压/心率升高，使化合物更适合。